Tuesday, July 30, 2024 9:49:26 PM
Gary, you do have a point that publicity may matter a lot but
this may take some months before more information is
disseminated about UK patients undergoing this new
immunotherapeutic treatment whereas the publicity would
have spread even faster if approval had been obtained in a larger
market (e.g. USA).
Furthermore, with time, the lawsuit could also generate good
publicity especially if a few rapid settlements could be arranged
with the criminals or articles begin to appear in the press concerning
a trial that Laura Posner may be pursuing.
Given enough time, all of this may indirectly keep the SP from
falling of the cliff.
Once Flaskworks comes on board and a major partnership is sealed,
everything will start to look even better but that again may take some time.
this may take some months before more information is
disseminated about UK patients undergoing this new
immunotherapeutic treatment whereas the publicity would
have spread even faster if approval had been obtained in a larger
market (e.g. USA).
Furthermore, with time, the lawsuit could also generate good
publicity especially if a few rapid settlements could be arranged
with the criminals or articles begin to appear in the press concerning
a trial that Laura Posner may be pursuing.
Given enough time, all of this may indirectly keep the SP from
falling of the cliff.
Once Flaskworks comes on board and a major partnership is sealed,
everything will start to look even better but that again may take some time.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
